JP2023513704A - 高リスク筋層非浸潤性膀胱癌を治療するためのｆｇｆｒチロシンキナーゼ阻害剤 - Google Patents

高リスク筋層非浸潤性膀胱癌を治療するためのｆｇｆｒチロシンキナーゼ阻害剤 Download PDF

Info

Publication number
JP2023513704A
JP2023513704A JP2022548599A JP2022548599A JP2023513704A JP 2023513704 A JP2023513704 A JP 2023513704A JP 2022548599 A JP2022548599 A JP 2022548599A JP 2022548599 A JP2022548599 A JP 2022548599A JP 2023513704 A JP2023513704 A JP 2023513704A
Authority
JP
Japan
Prior art keywords
fgfr
patient
inhibitor
fgfr3
fgfr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022548599A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023513704A5 (https=
Inventor
モンガ，マニッシュ
アリ ベーグ，マハディ
Original Assignee
ヤンセン ファーマシューティカ エヌ．ベー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカ エヌ．ベー． filed Critical ヤンセン ファーマシューティカ エヌ．ベー．
Publication of JP2023513704A publication Critical patent/JP2023513704A/ja
Publication of JP2023513704A5 publication Critical patent/JP2023513704A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022548599A 2020-02-12 2021-02-11 高リスク筋層非浸潤性膀胱癌を治療するためのｆｇｆｒチロシンキナーゼ阻害剤 Withdrawn JP2023513704A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062975547P 2020-02-12 2020-02-12
US62/975,547 2020-02-12
US202063018914P 2020-05-01 2020-05-01
US63/018,914 2020-05-01
US202063118475P 2020-11-25 2020-11-25
US63/118,475 2020-11-25
PCT/EP2021/053385 WO2021160764A1 (en) 2020-02-12 2021-02-11 Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer

Publications (2)

Publication Number Publication Date
JP2023513704A true JP2023513704A (ja) 2023-04-03
JP2023513704A5 JP2023513704A5 (https=) 2024-02-21

Family

ID=74666675

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022548599A Withdrawn JP2023513704A (ja) 2020-02-12 2021-02-11 高リスク筋層非浸潤性膀胱癌を治療するためのｆｇｆｒチロシンキナーゼ阻害剤

Country Status (14)

Country Link
US (1) US20230110113A1 (https=)
EP (1) EP4103185A1 (https=)
JP (1) JP2023513704A (https=)
KR (1) KR20220140781A (https=)
CN (1) CN115103678A (https=)
AU (1) AU2021220285A1 (https=)
BR (1) BR112022015827A2 (https=)
CA (1) CA3162962A1 (https=)
IL (1) IL295514A (https=)
JO (1) JOP20220182A1 (https=)
MX (1) MX2022009905A (https=)
PH (1) PH12022552093A1 (https=)
TW (1) TW202143970A (https=)
WO (1) WO2021160764A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL312063A (en) * 2021-10-12 2024-06-01 Taris Biomedical Llc Ardafitinib formulations and systems for intravesical administration
KR20240145513A (ko) * 2022-02-18 2024-10-07 타리스 바이오메디컬 엘엘씨 에르다피티닙 제형 및 방광내 투여를 위한 삼투성 시스템
KR20250143348A (ko) * 2023-02-13 2025-10-01 타리스 바이오메디컬 엘엘씨 방광암 치료에 사용하기 위한 방광내 투여용 에르다피티닙
EP4665341A1 (en) * 2023-02-13 2025-12-24 Janssen Pharmaceutica NV Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer
CN120731077A (zh) * 2023-02-17 2025-09-30 塔里斯生物医药公司 膀胱内施用厄达替尼以用于治疗膀胱癌

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
EP0951541B1 (en) 1995-07-31 2005-11-30 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
BRPI0611375A2 (pt) 2005-05-23 2010-08-31 Novartis Ag formas cristalinas e outras de sais de ácido láctico de 4-amino-5-flúor-3-[6-(4-metilpiperazin-1-il)-1h-benzimid azol-2-il]-1h-quinolin-2-ona
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
KR102470456B1 (ko) * 2014-09-26 2022-11-23 얀센 파마슈티카 엔.브이. Fgfr 억제제를 사용한 치료에 반응할 암 환자를 확인하는 데 있어서 fgfr 돌연변이 유전자 패널의 사용
TWI719960B (zh) * 2015-02-10 2021-03-01 英商阿斯迪克治療公司 新穎組成物
HUE062453T2 (hu) * 2017-02-06 2023-11-28 Janssen Pharmaceutica Nv Rákbetegség kezelése
TWI798199B (zh) * 2017-02-06 2023-04-11 比利時商健生藥品公司 癌症治療

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CLIN CANCER RES, vol. 23, no. 12, JPN6025006272, 2017, pages 3003 - 3011, ISSN: 0005722455 *
CLINICALTRIALS.GOV ID NCT04172675, VERSION 4: 2020-01-30 [オンライン], JPN6025006273, 30 January 2020 (2020-01-30), pages 1 - 20, ISSN: 0005722456 *
MOL CANCER THER, vol. 16, no. 6, JPN6025006270, 2017, pages 1010 - 1020, ISSN: 0005722453 *
PLOS ONE, vol. Vol. 7, No. 11, Article No. e50690, JPN6025006271, 2012, pages 1 - 11, ISSN: 0005722454 *

Also Published As

Publication number Publication date
AU2021220285A1 (en) 2022-10-06
IL295514A (en) 2022-10-01
US20230110113A1 (en) 2023-04-13
TW202143970A (zh) 2021-12-01
JOP20220182A1 (ar) 2023-01-30
BR112022015827A2 (pt) 2022-10-04
KR20220140781A (ko) 2022-10-18
CA3162962A1 (en) 2021-08-19
WO2021160764A1 (en) 2021-08-19
EP4103185A1 (en) 2022-12-21
CN115103678A (zh) 2022-09-23
PH12022552093A1 (en) 2023-11-29
MX2022009905A (es) 2022-08-25

Similar Documents

Publication Publication Date Title
JP2023513704A (ja) 高リスク筋層非浸潤性膀胱癌を治療するためのｆｇｆｒチロシンキナーゼ阻害剤
US20220175768A1 (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
JP2025156297A (ja) 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤
US20250000858A1 (en) Fgfr tyrosine kinase inhibitors for the treatment of advanced solid tumors
JP2026505598A (ja) 高リスク筋層非浸潤性膀胱癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤
HK40081735A (en) Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer
HK40064235A (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
EA052400B1 (ru) Ингибиторы тирозинкиназ fgfr для лечения уротелиальной карциномы
HK40126446A (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250218

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250516

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250718

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250818

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260304

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20260330